Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00316030 · ClinicalTrials.gov registry record · Phase 1

Study of Bexarotene in Patients With Acute Myeloid Leukemia

A Phase 1 study of Acute Myeloid Leukemia and AML, sponsored by Abramson Cancer Center at Penn Medicine.

Completed
Registry status
Phase 1
Development phase
54
Enrollment target
1
Study location

NCT00316030: Completed Phase 1 study of Acute Myeloid Leukemia and AML, sponsored by Abramson Cancer Center at Penn Medicine.

NCT00316030 is a Phase 1 study of Acute Myeloid Leukemia and AML that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 54 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00316030, a Phase 1 study of Acute Myeloid Leukemia and AML, has completed, sponsored by Abramson Cancer Center at Penn Medicine.

COMPLETED
Registry status
Phase 1
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

Bexarotene may be useful in the treatment of Acute Myeloid Leukemia (AML). This is the first study on the use of bexarotene to treat patients with AML. The main purpose of this study is to establish the proper dose of bexarotene when used to treat AML. The side effect profile of bexarotene in patients with AML will also be explored.

Conditions Studied

Acute Myeloid Leukemia AML

Interventions

  • DRUG Bexarotene

Study Locations (1)

Pennsylvania

  • Abramson Cancer Center of University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2004-01
Phase Phase 1
Abramson Cancer Center at Penn Medicine

402 total trials

What the finished NCT00316030 record still lists

NCT00316030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (53% lower).

The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Bexarotene is the first listed.

NCT00316030 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00316030 about?

NCT00316030 is a clinical study titled "Study of Bexarotene in Patients With Acute Myeloid Leukemia". Bexarotene may be useful in the treatment of Acute Myeloid Leukemia (AML). This is the first study on the use of bexarotene to treat patients with AML. The main purpose of this study is to establish the proper dose of bexarotene when used to treat AML. The side effect profile of bexarotene in patien...

What is the current status of trial NCT00316030?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2004-01.

What conditions does trial NCT00316030 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, AML.

What interventions are being tested in trial NCT00316030?

The interventions under investigation include: Bexarotene (DRUG).

Who is sponsoring clinical trial NCT00316030?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00316030 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00316030's enrollment target sits among peer trials

54 133rd of 306 higher than 171 of 306 other Acute Myeloid Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00316030, the US trial registry maintained by the National Library of Medicine. NCT00316030 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.